A phase 1, dose-escalation, first-in-human study of ARQ 087, an oral pan-FGFR inhibitor, in adult subjects with advanced solid tumors

被引：0
|
作者：
Papadopoulos, K. [1 ]
Tolcher, A. [1 ]
Kittaneh, M. [2 ]
Patniak, A. [1 ]
Rasco, D. [1 ]
Chambers, G. [1 ]
Newth, G. [2 ]
Savage, R. [3 ]
Hall, T. [3 ]
Schwartz, B. [3 ]
Kazakin, J. [3 ]
LoRusso, P. [2 ]
机构：
[1] South Texas Accelerated Res Therapeut, Med Oncol, San Antonio, TX USA
[2] Karmanos Canc Inst, Ctr Translat Therapeut, Detroit, MI USA
[3] ArQule Inc, Clin Dev, Woburn, MA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)70515-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
389
引用
收藏
页码：125 / 125
页数：1
相关论文
共 50 条
  • [1] A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
    Papadopoulos, K. P.
    El-Rayes, B. F.
    Tolcher, A. W.
    Patnaik, A.
    Rasco, D. W.
    Harvey, R. D.
    LoRusso, P. M.
    Sachdev, J. C.
    Abbadessa, G.
    Savage, R. E.
    Hall, T.
    Schwartz, B.
    Wang, Y.
    Kazakin, J.
    Shaib, W. L.
    BRITISH JOURNAL OF CANCER, 2017, 117 (11) : 1592 - 1599
  • [2] A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
    K P Papadopoulos
    B F El-Rayes
    A W Tolcher
    A Patnaik
    D W Rasco
    R D Harvey
    P M LoRusso
    J C Sachdev
    G Abbadessa
    R E Savage
    T Hall
    B Schwartz
    Y Wang
    J Kazakin
    W L Shaib
    British Journal of Cancer, 2017, 117 : 1592 - 1599
  • [3] Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.
    Papadopoulos, Kyriakos P.
    Tolcher, Anthony W.
    Patnaik, Amita
    Rasco, Drew Warren
    Chambers, Glenda
    Beeram, Murali
    Savage, Ronald
    Hall, Terence
    Schwartz, Brian E.
    Kazakin, Julia
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
    Infante, Jeffrey R.
    Mendelson, David S.
    Burris, Howard A., III
    Bendell, Johanna C.
    Tolcher, Anthony W.
    Gordon, Michael S.
    Gillenwater, Heidi H.
    Arastu-Kapur, Shirin
    Wong, Hansen L.
    Papadopoulos, Kyriakos P.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (02) : 216 - 224
  • [5] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
    Jeffrey R. Infante
    David S. Mendelson
    Howard A. Burris
    Johanna C. Bendell
    Anthony W. Tolcher
    Michael S. Gordon
    Heidi H. Gillenwater
    Shirin Arastu-Kapur
    Hansen L. Wong
    Kyriakos P. Papadopoulos
    Investigational New Drugs, 2016, 34 : 216 - 224
  • [6] First-in-human phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors
    Azaro, A.
    Rodon, J.
    Herranz, M.
    Nuciforo, P.
    Prudkin, L.
    Lopez-Busto, N.
    Balandraud, S.
    Cattan, V.
    Jacquet-Bescond, A.
    Marfai, L.
    Pauly, J.
    Postel-Vinay, S.
    Hollebecque, A.
    Soria, J. C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S54 - S54
  • [7] First-in-human phase 1 dose-escalation study of DS-6051b, an oral ROS1 and NTRK inhibitor, in subjects with advanced solid tumors
    Papadopoulos, Kyriakos P.
    Borazanci, Erkut
    Von Hoff, Daniel
    Gandhi, Leena
    Patnaik, Amita
    Tachibana, Masaya
    Zahir, Hamim
    Gajee, Roohi
    Goldberg, Tern
    Senaldi, Giorgio
    Ou, Sai-Hong
    CANCER RESEARCH, 2016, 76
  • [8] Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors.
    Voss, Martin Henner
    Hierro, Cinta
    Heist, Rebecca Suk
    Cleary, James M.
    Meric-Bernstam, Funda
    Gandhi, Leena
    Ishii, Nobuya
    Kirpicheva, Yulia
    Nicolas-Metral, Valerie
    Pokorska-Bocci, Anna
    Purcea, Daniela
    Vaslin, Anne
    Moulon, Corinne
    Zanna, Claudio
    Flaherty, Keith
    Tabernero, Josep
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] First-in-human Phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors.
    Hollebecque, Antoine
    Soria, Jean-Charles
    Bahleda, Ratislav
    Lopez-Busto, Natividad
    Jacquet-Bescond, Anne
    Burbridge, Mike F.
    Valerie, Cattan
    Pauly, Jeanne
    Herranz, Maria
    Azaro, Analia
    Depil, Stephane
    Rodon, Jordi
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [10] PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF ARQ 087, A NOVEL PAN-FGFR INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING INTRAHEPATIC CHOLAN-GIOCARCINOMA.
    Savage, R.
    Trinh, M.
    Dupuis, M.
    Marier, J. F.
    Schwartz, B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S77 - S77
12345